HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells.

Abstract
Osteosarcoma (OS) is a malignant neoplasia in bone, characterized with main occurrence in teenagers. Calycosin (CC), a bioactive compound, is found to play potent pharmacological effects against cancer. Our previous study indicates CC-exerted benefits for anti-OS effect. However, further molecular mechanism behind this action needs to be investigated. In this study, human OS samples and clinical data were collected and used for further test and analysis. In addition, human osteosarcoma cell line (143B) and tumor-xenograft nude mice were used to evaluate antineoplastic activities of CC through a series of biochemical methods and immunoassays, respectively. Compared with non-OS controls, human OS samples showed increased levels of neoplastic microRNA-223 (miR-223), and elevated expressions of NF-κBp65, IκBα proteins in tumor cells. In cell culture study, CC-treated 143B cells showed reduced cell growth, increased lactic dehydrogenase (LD) content, and downregulated cellular miR-223 level. Immunolabeled cells of proliferating cell nuclear antigen, B-cell lymphoma 2 (Bcl-2), poly(ADP-ribose) polymerase (PARP) in CC treatments were decreased dose-dependently, while caspase-3 positive cells were elevated. Further, protein expressions of NF-κBp65, IκBα in CC-treated cells were downregulated. In addition, tumor-xenograft nude mice followed by CC treatments exhibited reductions of tumor mass, miR-223 levels, and Bcl-2, PARP-positive cells, as well as downregulations of NF-κBp65, IκBα protein expressions in OS samples. Taken together, these experimental findings reveal that CC exhibits potential pharmacological activities against OS through inducing apoptosis and inhibiting miR-223-IκBα signaling pathway in neoplastic cells.
AuthorsRubiao Qiu, Gang Ma, Xueyu Li, Qunfeng Shi, Xinning Li, Xiong Zhou, Yuanyuan Tang, Zhaodi Xie, Shijie Liao, Yiwu Qin, Ruyue Wang, Yu Ye, Jiefeng Luo, Jianfeng Zhang
JournalJournal of cellular biochemistry (J Cell Biochem) Vol. 120 Issue 6 Pg. 10697-10706 (06 2019) ISSN: 1097-4644 [Electronic] United States
PMID30652346 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2019 Wiley Periodicals, Inc.
Chemical References
  • Antineoplastic Agents, Phytogenic
  • BCL2 protein, human
  • Isoflavones
  • MIRN223 microRNA, human
  • MicroRNAs
  • Proto-Oncogene Proteins c-bcl-2
  • RELA protein, human
  • Transcription Factor RelA
  • 7,3'-dihydroxy-4'-methoxyisoflavone
  • NF-KappaB Inhibitor alpha
  • L-Lactate Dehydrogenase
  • Poly(ADP-ribose) Polymerases
Topics
  • Adolescent
  • Animals
  • Antineoplastic Agents, Phytogenic (pharmacology)
  • Bone Neoplasms (drug therapy, genetics, pathology, surgery)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Child
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Isoflavones (pharmacology)
  • L-Lactate Dehydrogenase (genetics, metabolism)
  • Male
  • Mice
  • Mice, Nude
  • MicroRNAs (genetics, metabolism)
  • NF-KappaB Inhibitor alpha (genetics, metabolism)
  • Osteosarcoma (drug therapy, genetics, pathology, surgery)
  • Poly(ADP-ribose) Polymerases (genetics, metabolism)
  • Proto-Oncogene Proteins c-bcl-2 (genetics, metabolism)
  • Signal Transduction
  • Transcription Factor RelA (genetics, metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: